Prophylactic or Preemptive Donor-Derived CD19 CAR-T Cell Infusion for Preventing Relapse in High-Risk B-ALL after Allogeneic Hematopoietic Stem Cell Transplantation
Wenyi Lu(Tianjin First Center Hospital), Mingfeng Zhao(Nankai University), Xue Bai(Southwest Medical University), Zunmin Zhu(Zhengzhou University), Ting Yuan(Goethe University Frankfurt), Haibo Zhu(Tianjin First Center Hospital), Michael Maschan(Russian Children's Clinical Hospital), Hairong Lv(Tsinghua University), Tianle Xie(Nankai University), Alexander G. Gabibov(Institute of Bioorganic Chemistry), Bing Wang(Beijing Forestry University), Zhao Wang(Capital Medical University), Meng Zhang(Scripps Research Institute), Jiaxi Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongkai Zhang(Nankai University), Xia Xiao(Hebei Medical University), А. В. Степанов(Institute of Bioorganic Chemistry), Xinping Cao(Sun Yat-sen University), Rui Sun(Nankai University), Yu Zhang(Kunming University of Science and Technology), Juanxia Meng(Nankai University), Haotian Meng(University of Jinan), Yedi Pu(Tianjin First Center Hospital), Yuxin An(Tianjin Medical University), Xiaomei Zhang(Tang Hospital), Xin Jin(Nankai University)
Cited by 1
Related Papers
Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
|Theranostics|2020|397
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
|Journal of Hematology & Oncology|2022|149